Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

benzinga.com/news/health-care/25/06/46053581/exelixis-targets-5-billion-in-sales-with-promising-data-in-key-colorectal-cancer-drug-trial-stoc

On Sunday, Exelixis, Inc. (NASDAQ:EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab.
The study includes patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer…

This story appeared on benzinga.com, 2025-06-23 14:37:05.
The Entire Business World on a Single Page. Free to Use →